Royalty Report: Drugs, Diagnostic, Biotechnology – Collection: 28830

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Diagnostic
  • Biotechnology
  • Therapeutic
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28830

License Grant
Pursuant to the Agreement, the Danish Licensor granted the United Kingdom Licensee an exclusive, worldwide, License with the right to subLicense.
License Property
The technology includes certain patents to use certain antigens in a diagnostic kit for in vitro diagnosis of TB in humans using an ELISPOT-based detection of interferon-gamma producing T cells using any fluid sample other than whole blood in the diagnostic assay.

“Elispot” shall mean an in vitro assay to detect cytokine secreting T-cells reacting to one or more antigens or peptides by capturing cytokine released from those reactive T cells in the immediate vicinity of the T-cells by an immobilized primary antibody.

IPSCIO Record ID: 203391

License Grant
In furtherance of the settlement of the Lawsuit, Licensor is willing to license certain of its intellectual property to Licensee.

Licensor hereby grants to Licensee and its Affiliates a non-exclusive, royalty-bearing license to the Patent Rights, without the right to sublicense except as approved by Licensor in writing, to make, have made, use, sell and have sold Mab-based Licensed Products in the Territory, except products utilizing the format technology that is proprietary and that, as of today, is provided by Party A to Licensor in the test format in Licensor’s current Witness heartworm diagnostic products. For purposes of clarity, Licensor hereby acknowledges Licensee’s right to have such Mab-based Licensed Products or any component thereof manufactured by a third party. This license grant is limited only to Licensee’s own Mab-based Licensed Products whereas products which Licensee may distribute for other parties that may otherwise infringe the Patent Rights are specifically excluded, except as approved by Licensor in writing.

Licensor hereby also grants to Licensee and its Affiliates a non-exclusive, royalty-free license to the Patent Rights, without the right to sublicense except as approved by Licensor in writing, to make, have made, use, sell and have sold Di33-based Licensed Products in the Territory, except products utilizing the format technology that is proprietary and that, as of today, is provided by Party A to Licensor in the test format in Licensor’s current Witness heartworm diagnotic products. For purposes of clarity,  Licensor hereby acknowledges Licensee’s right to have such Di33-based Licensed Products or any component thereof manufactured by a third party. Furthermore, the Parties agree that, if a product qualifies as both a Mab-based Licensed Product and a Di33-based Licensed Product, it shall be subject to royalties. This license grant is limited only to Licensee’s own Di33-based Licensed Products whereas products which Licensee may distribute for other parties that may otherwise infringe the Patent Rights are specifically excluded, except as approved by Licensor in writing.

License Property
Patent Rights shall mean the ’631 Patent.  Licensor is the owner of United States Patent No. 4,789,631 issued on December 6, 1988, entitled “Immunoassay for Anti-Dirofilaria Immitis Antibody” (the ’631 Patent).

Licensed Products shall mean Mab-based Licensed Products and/or Di33-based Licensed Products.

Mab-based Licensed Products shall mean any heartworm antigen detection test product or part thereof having or using at least one monoclonal antibody that reacts with Dirofilaria immitis antigenic extract, including any said heartworm antigen detection test product or part thereof within the scope of a claim in the Patent Rights or manufactured by a process within the scope of a claim in the Patent Rights. For avoidance of doubt, the Parties agree that Licensees SOLO STEP® CH product and canine and feline reference laboratory heartworm antigen detection tests using such a monoclonal antibody are “Mab-based Licensed Products”.

Di33-based Licensed Products ” shall mean any heartworm antibody detection test product or part thereof using at least one recombinant Di33 protein, wherein a Di33 protein has properties as set forth in the ‘569 Patent, including any said heartworm antibody detection test product or part thereof within the scope of a claim in the Patent Rights or manufactured by a process within the scope of a claim in the Patent Rights.

Field of Use
This agreement pertains to health products for dogs, cats and horses relating to developing, manufacturing and marketing veterinary diagnostics, vaccines and other animal health related products worldwide.

IPSCIO Record ID: 26289

License Grant
The Licensor hereby grants to the Israeli Company, a non-exclusive, worldwide license to make, have made, market, distribute (directly or by means of local distributors), and Sell Licensed Products. Technology, generally characterized as Diagnostic Methods for Chlamydia Pneumoniae, Tech I.D. #07-86-34,  is covered by certain patent and know-how rights.
License Property
The Technology is comprised of three methods and associated materials for the detection and/or diagnosis of Chlamydia Pneumoniae, namely Monoclonal antibody-based antigen detection, serological antibody detection, and nucleic acid probe based detection.
Field of Use
“Field of Use”, as used herein, shall mean those portions of the Technology directly pertaining to methods and materials for the serological detection of antibodies, and their use by the Licensee to develop arid market assays.  The Field of Use expressly excludes the nucleic acid probe and Monoclonal antibody – based detection materials and methods of detecting Chlamydia Pneumoniae and expressly excludes the right to sell the diagnostic test results.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.